ibi188

mAbexperimental

Clinical trial activity

6 trials · 12 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Dec 11, 2018 (NCT03717103)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04861948Phase 1May 25, 2021Central South University, Chinese Academy of Medical Sciences, Chongqing Medical University, Innovent Biologics (Suzhou) Co. Ltd., Nanjing Medical University, Nanjing University, Peking University, Soochow University, Southern Medical University, Tianjin Medical University, Xuzhou Medical University, Zhejiang University
NCT04485052Phase 1/Phase 2 (Phase 2)Sep 25, 2020Innovent Biologics (Suzhou) Co. Ltd.
NCT04511975Phase 1Aug 24, 2020Innovent Biologics (Suzhou) Co. Ltd.
NCT04485065Phase 1Aug 2, 2020Innovent Biologics (Suzhou) Co. Ltd.
NCT03763149Phase 1Jan 11, 2019Innovent Biologics (Suzhou) Co. Ltd.
NCT03717103Phase 1Dec 11, 2018Innovent Biologics (Suzhou) Co. Ltd.
Showing 6 of 6 trials
Page 1 / 1

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Innovent Biologics (Suzhou) Co. Ltd.For profit6622018
Central South UniversityAcademic/Hospital1012021
Chinese Academy of Medical SciencesAcademic/Hospital1012021
Chongqing Medical UniversityAcademic/Hospital1012021
Nanjing Medical UniversityAcademic/Hospital1012021
Nanjing UniversityAcademic/Hospital1012021
Peking UniversityAcademic/Hospital1012021
Soochow UniversityAcademic/Hospital1012021
Southern Medical UniversityAcademic/Hospital1012021
Tianjin Medical UniversityAcademic/Hospital1012021
Xuzhou Medical UniversityAcademic/Hospital1012021
Zhejiang UniversityAcademic/Hospital1012021
12 organizations
Page 1 / 1